» Articles » PMID: 14586540

The Plant-derived Hallucinogen, Salvinorin A, Produces Kappa-opioid Agonist-like Discriminative Effects in Rhesus Monkeys

Overview
Specialty Pharmacology
Date 2003 Oct 31
PMID 14586540
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Salvinorin A is the active component of the hallucinogenic plant Salvia divinorum. The potential mode of action of this hallucinogen was unknown until recently. A recent in vitro study detected high affinity and efficacy of salvinorin A at kappa-opioid receptors. It was postulated that salvinorin A would produce discriminative stimulus effects similar to those of a high efficacy kappa-agonist (U69,593) in rhesus monkeys.

Methods: Monkeys were previously trained to discriminate U69,593 (0.0056 or 0.013 mg/kg; s.c.) from vehicle in a food-reinforced FR20 (fixed ratio 20) operant conditioning procedure (n=3). The ability of salvinorin A to cause generalization (> or =90% U69,593-appropriate responding) was examined in time course and cumulative dose-effect curve studies.

Results: All subjects dose-dependently emitted full U69,593-appropriate responding after salvinorin A (0.001-0.032 mg/kg, SC). Salvinorin A-induced generalization started 5-15 min after injection, and dissipated by 120 min. The opioid antagonist quadazocine (0.32 mg/kg) fully blocked the effects of salvinorin A. The kappa-selective antagonist GNTI (1 mg/kg; 24 h pretreatment) did not cause significant antagonism of the effects of salvinorin A (GNTI, under these conditions, was only effective as an antagonist in two of three monkeys). The NMDA antagonist ketamine (0.1-3.2 mg/kg) was not generalized by any subject, indicating that not all compounds that produce hallucinogenic or psychotomimetic effects in humans are generalized by subjects trained to discriminate U69,593.

Conclusions: The naturally occurring hallucinogen salvinorin A produces discriminative stimulus effects similar to those of a high efficacy kappa-agonist in non-human primates.

Citing Articles

Pharmacokinetics and Pharmacodynamics of Salvinorin A and : Clinical and Forensic Aspects.

Machado Brito-da-Costa A, Dias-da-Silva D, Gomes N, Dinis-Oliveira R, Madureira-Carvalho A Pharmaceuticals (Basel). 2021; 14(2).

PMID: 33546518 PMC: 7913753. DOI: 10.3390/ph14020116.


Clinical applications of hallucinogens: A review.

Garcia-Romeu A, Kersgaard B, Addy P Exp Clin Psychopharmacol. 2016; 24(4):229-68.

PMID: 27454674 PMC: 5001686. DOI: 10.1037/pha0000084.


Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.

Butelman E, Kreek M Front Pharmacol. 2015; 6:190.

PMID: 26441647 PMC: 4561799. DOI: 10.3389/fphar.2015.00190.


Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Kivell B, Ewald A, Prisinzano T Adv Pharmacol. 2014; 69:481-511.

PMID: 24484985 PMC: 4128345. DOI: 10.1016/B978-0-12-420118-7.00012-3.


LC-MS/MS quantification of salvinorin A from biological fluids.

Caspers M, Williams T, Lovell K, Lozama A, Butelman E, Kreek M Anal Methods. 2014; 5(24).

PMID: 24416081 PMC: 3885280. DOI: 10.1039/C3AY40810H.


References
1.
Butelman E, Ball J, Kreek M . Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys. Psychopharmacology (Berl). 2002; 164(1):115-20. DOI: 10.1007/s00213-002-1195-y. View

2.
Valdes 3rd L, Diaz J, Paul A . Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol. 1983; 7(3):287-312. DOI: 10.1016/0378-8741(83)90004-1. View

3.
Giroud C, Felber F, Augsburger M, Horisberger B, Rivier L, Mangin P . Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland. Forensic Sci Int. 2000; 112(2-3):143-50. DOI: 10.1016/s0379-0738(00)00180-8. View

4.
France C, Snyder A, Woods J . Analgesic effects of phencyclidine-like drugs in rhesus monkeys. J Pharmacol Exp Ther. 1989; 250(1):197-201. View

5.
Bowdle T, Radant A, Cowley D, Kharasch E, Strassman R, Roy-Byrne P . Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998; 88(1):82-8. DOI: 10.1097/00000542-199801000-00015. View